Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 306-311

  Erfani, Nasrollah ^a   Mehrabadi, Shayesteh Mofakhami ^b   Ghayumi, Mohammad Ali ^c   Haghshenas, Mohammad Reza ^a   Mojtahedi, Zahra ^a   Ghaderi, Abbas ^a   Amani, Davar ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CTLA 4; FoxP3; Lung cancer; Non small cell lung cancer; Regulatory T cells; Tumor immunology

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM STAGING; T-LYMPHOCYTES, REGULATORY;

EID: 84863783251     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.011     Document Type: Article

References (43)

1. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294.
2. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
3. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
4. Alegre M.L., Shiels H., Thompson C.B., Gajewski T.F. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998, 161:3347-3356.
5. Liyanage U.K., Goedegebuure P.S., Moore T.T., Viehl C.T., Moo-Young T.A., Larson J.W., et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 2006, 29:416-424.
6. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
7. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65:2457-2464.
8. Yokokawa J., Cereda V., Remondo C., Gulley J.L., Arlen P.M., Schlom J., et al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008, 14:1032-1040.
9. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
10. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
11. Sasada T., Kimura M., Yoshida Y., Kanai M., Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003, 98:1089-1099.
12. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H., Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003, 9:4404-4408.
13. Schaefer C., Kim G.G., Albers A., Hoermann K., Myers E.N., Whiteside T.L. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005, 92:913-920.
14. Javia L.R., Rosenberg S.A. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003, 26:85-93.
15. Viguier M., Lemaitre F., Verola O., Cho M.S., Gorochov G., Dubertret L., et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-1453.
16. Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., Ansell S.M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107:3639-3646.
17. Motta M., Rassenti L., Shelvin B.J., Lerner S., Kipps T.J., Keating M.J., et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005, 19:1788-1793.
18. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
19. Wang X., Zheng J., Liu J., Yao J., He Y., Li X., et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005, 75:468-476.
20. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
21. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-257.
22. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
23. Shevach E.M. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001, 193:F41-F46.
24. Liu L., Yao J., Ding Q., Huang S. CD4+CD25high regulatory cells in peripheral blood of NSCLC patients. J Huazhong Univ Sci Technolog Med Sci 2006, 26:548-551.
25. Okita R., Saeki T., Takashima S., Yamaguchi Y., Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005, 14:1269-1273.
26. Kono K., Kawaida H., Takahashi A., Sugai H., Mimura K., Miyagawa N., et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006, 55:1064-1071.
27. Shen X., Li N., Li H., Zhang T., Wang F., Li Q. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010.
28. Shiratori T., Miyatake S., Ohno H., Nakaseko C., Isono K., Bonifacino J.S., et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 1997, 6:583-589.
29. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
30. Erfani N., Razmkhah M., Ghaderi A. Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Cancer Invest 2010, 28:828-832.
31. Ayukawa H., Matsubara T., Kaneko M., Hasegawa M., Ichiyama T., Furukawa S. Expression of CTLA-4 (CD152) in peripheral blood T cells of children with influenza virus infection including encephalopathy in comparison with respiratory syncytial virus infection. Clin Exp Immunol 2004, 137:151-155.
32. Vanky F., Nagy N., Hising C., Sjovall K., Larson B., Klein E. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 1997, 43:317-323.
33. Christeli E., Zoumpourlis V., Kiaris H., Ergazaki M., Vassilaros S., Spandidos D. TGF-beta 1 overexpression in breast cancer. Oncol Rep 1996, 3:1115-1118.
34. Friess H., Korc M., Buchler M.W. Molecular biology of pancreatic cancer: overexpression of fibroblast growth factors. Chirurg 1994, 65:604-610.
35. Park H.B., Paik D.J., Jang E., Hong S., Youn J. Acquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25- T cells. Int Immunol 2004, 16:1203-1213.
36. Fantini M.C., Becker C., Monteleone G., Pallone F., Galle P.R., Neurath M.F. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004, 172:5149-5153.
37. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
38. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
39. Ribas A., Glaspy J.A., Lee Y., Dissette V.B., Seja E., Vu H.T., et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004, 27:354-367.
40. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
41. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-832.
42. O'Day S.J., Hamid O., Urba W.J. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007, 110:2614-2627.
43. Feng L.L., Wang X. Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy. Chin Med J (Engl) 2010, 123:3334-3342.